Cargando…
Omalizumab in Chronic Spontaneous Urticaria Refractory to Conventional Therapy: An Italian Retrospective Clinical Analysis with Suggestions for Long-Term Maintenance Strategies
INTRODUCTION: Omalizumab is indicated for the treatment of patients affected by chronic spontaneous urticaria (CSU) refractory to antihistamines. The aim of this study was to assess the efficacy, safety, and recurrence of symptoms in a real-life experience of omalizumab as an add-on therapy for H(1)...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002323/ https://www.ncbi.nlm.nih.gov/pubmed/29770909 http://dx.doi.org/10.1007/s13555-018-0240-7 |
_version_ | 1783332176430891008 |
---|---|
author | Mandel, Victor D. Guanti, Mario B. Liberati, Serena Demonte, Antongiulio Pellacani, Giovanni Pepe, Patrizia |
author_facet | Mandel, Victor D. Guanti, Mario B. Liberati, Serena Demonte, Antongiulio Pellacani, Giovanni Pepe, Patrizia |
author_sort | Mandel, Victor D. |
collection | PubMed |
description | INTRODUCTION: Omalizumab is indicated for the treatment of patients affected by chronic spontaneous urticaria (CSU) refractory to antihistamines. The aim of this study was to assess the efficacy, safety, and recurrence of symptoms in a real-life experience of omalizumab as an add-on therapy for H(1)-antihistamine-refractory CSU patients (refractory CSU). METHODS: A retrospective review of the clinical records of all refractory CSU treated with omalizumab at our dermatology center from June 2014 to April 2017 was performed. Patients previously treated with second-generation antihistamines at a fourfold increased dose without clinical responses at 4 weeks of treatment were selected. Omalizumab was administered at a single dosage of 300 mg every 4 weeks for 6 months. Disease severity was assessed using the 7-day Urticaria Activity Score (UAS7). RESULTS: Eighteen patients (14 women; mean age 51 years, range 25–74) were enrolled. Mean UAS7 at baseline was 27.3 (range 15–38). Symptoms improved in all patients at 4 weeks (UAS7 = 16.1, range 0–36). Treatment was completed in 17 patients (94.4%), and among these, a complete response (UAS7 = 0) was registered in 10 patients (58.8%). Adverse events included thrombocytopenia in 1 patient (5.6%) at 16 weeks; therapy was suspended after 20 weeks and the complication was resolved, resulting in a freedom from major adverse events of 94.4%. Symptom recurrence occurred in 3 patients (17.6%) at 4, 5, and 7 months from the end of the primary therapy. Retreatment with omalizumab was successful without any adverse effects. Mean follow-up was 9.5 months (range 1–28). CONCLUSION: Add-on omalizumab therapy for refractory CSU in a real-life setting seems to be effective and safe with a relatively low incidence of symptom recurrence. Further research should investigate personalized omalizumab treatment dosages and administration intervals, and the identification of biomarkers for future treatment algorithms. |
format | Online Article Text |
id | pubmed-6002323 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-60023232018-06-29 Omalizumab in Chronic Spontaneous Urticaria Refractory to Conventional Therapy: An Italian Retrospective Clinical Analysis with Suggestions for Long-Term Maintenance Strategies Mandel, Victor D. Guanti, Mario B. Liberati, Serena Demonte, Antongiulio Pellacani, Giovanni Pepe, Patrizia Dermatol Ther (Heidelb) Original Research INTRODUCTION: Omalizumab is indicated for the treatment of patients affected by chronic spontaneous urticaria (CSU) refractory to antihistamines. The aim of this study was to assess the efficacy, safety, and recurrence of symptoms in a real-life experience of omalizumab as an add-on therapy for H(1)-antihistamine-refractory CSU patients (refractory CSU). METHODS: A retrospective review of the clinical records of all refractory CSU treated with omalizumab at our dermatology center from June 2014 to April 2017 was performed. Patients previously treated with second-generation antihistamines at a fourfold increased dose without clinical responses at 4 weeks of treatment were selected. Omalizumab was administered at a single dosage of 300 mg every 4 weeks for 6 months. Disease severity was assessed using the 7-day Urticaria Activity Score (UAS7). RESULTS: Eighteen patients (14 women; mean age 51 years, range 25–74) were enrolled. Mean UAS7 at baseline was 27.3 (range 15–38). Symptoms improved in all patients at 4 weeks (UAS7 = 16.1, range 0–36). Treatment was completed in 17 patients (94.4%), and among these, a complete response (UAS7 = 0) was registered in 10 patients (58.8%). Adverse events included thrombocytopenia in 1 patient (5.6%) at 16 weeks; therapy was suspended after 20 weeks and the complication was resolved, resulting in a freedom from major adverse events of 94.4%. Symptom recurrence occurred in 3 patients (17.6%) at 4, 5, and 7 months from the end of the primary therapy. Retreatment with omalizumab was successful without any adverse effects. Mean follow-up was 9.5 months (range 1–28). CONCLUSION: Add-on omalizumab therapy for refractory CSU in a real-life setting seems to be effective and safe with a relatively low incidence of symptom recurrence. Further research should investigate personalized omalizumab treatment dosages and administration intervals, and the identification of biomarkers for future treatment algorithms. Springer Healthcare 2018-05-16 /pmc/articles/PMC6002323/ /pubmed/29770909 http://dx.doi.org/10.1007/s13555-018-0240-7 Text en © The Author(s) 2018 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Mandel, Victor D. Guanti, Mario B. Liberati, Serena Demonte, Antongiulio Pellacani, Giovanni Pepe, Patrizia Omalizumab in Chronic Spontaneous Urticaria Refractory to Conventional Therapy: An Italian Retrospective Clinical Analysis with Suggestions for Long-Term Maintenance Strategies |
title | Omalizumab in Chronic Spontaneous Urticaria Refractory to Conventional Therapy: An Italian Retrospective Clinical Analysis with Suggestions for Long-Term Maintenance Strategies |
title_full | Omalizumab in Chronic Spontaneous Urticaria Refractory to Conventional Therapy: An Italian Retrospective Clinical Analysis with Suggestions for Long-Term Maintenance Strategies |
title_fullStr | Omalizumab in Chronic Spontaneous Urticaria Refractory to Conventional Therapy: An Italian Retrospective Clinical Analysis with Suggestions for Long-Term Maintenance Strategies |
title_full_unstemmed | Omalizumab in Chronic Spontaneous Urticaria Refractory to Conventional Therapy: An Italian Retrospective Clinical Analysis with Suggestions for Long-Term Maintenance Strategies |
title_short | Omalizumab in Chronic Spontaneous Urticaria Refractory to Conventional Therapy: An Italian Retrospective Clinical Analysis with Suggestions for Long-Term Maintenance Strategies |
title_sort | omalizumab in chronic spontaneous urticaria refractory to conventional therapy: an italian retrospective clinical analysis with suggestions for long-term maintenance strategies |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002323/ https://www.ncbi.nlm.nih.gov/pubmed/29770909 http://dx.doi.org/10.1007/s13555-018-0240-7 |
work_keys_str_mv | AT mandelvictord omalizumabinchronicspontaneousurticariarefractorytoconventionaltherapyanitalianretrospectiveclinicalanalysiswithsuggestionsforlongtermmaintenancestrategies AT guantimariob omalizumabinchronicspontaneousurticariarefractorytoconventionaltherapyanitalianretrospectiveclinicalanalysiswithsuggestionsforlongtermmaintenancestrategies AT liberatiserena omalizumabinchronicspontaneousurticariarefractorytoconventionaltherapyanitalianretrospectiveclinicalanalysiswithsuggestionsforlongtermmaintenancestrategies AT demonteantongiulio omalizumabinchronicspontaneousurticariarefractorytoconventionaltherapyanitalianretrospectiveclinicalanalysiswithsuggestionsforlongtermmaintenancestrategies AT pellacanigiovanni omalizumabinchronicspontaneousurticariarefractorytoconventionaltherapyanitalianretrospectiveclinicalanalysiswithsuggestionsforlongtermmaintenancestrategies AT pepepatrizia omalizumabinchronicspontaneousurticariarefractorytoconventionaltherapyanitalianretrospectiveclinicalanalysiswithsuggestionsforlongtermmaintenancestrategies |